![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
Pronóstico del mercado europeo de virología hasta 2028: impacto de COVID-19 y análisis regional por tipo (prueba de diagnóstico, técnicas de control de infecciones virales, terapias antivirales e interferones), aplicación (infecciones de la piel y tejidos blandos, infecciones del tracto respiratorio, infecciones del tracto gastrointestinal, de transmisión sexual) Enfermedades Infecciosas del Tracto Urinario y Otros) y Usuario Final (Hospitales, Laboratorios de Diagnóstico, Empresas Farmacéuticas y Biotecnológicas e Institutos Académicos y de Investigación)
Introducción al mercado
El mercado europeo de virología incluye los mercados consolidados de Francia, Alemania, Reino Unido, España, Italia y el resto de Europa. . Europa ocupa una posición importante en el mercado de la virología y se espera que registre una vigorosa tasa de crecimiento durante el período previsto. El crecimiento del mercado se atribuye a los desarrollos de productos realizados por empresas de países como Alemania y el Reino Unido, a las sólidas actividades de investigación y desarrollo y al aumento de la financiación para la investigación de enfermedades emergentes. La influenza es una enfermedad mortal para las personas mayores con enfermedades crónicas. La mortalidad y la morbilidad por gripe son elevadas en Alemania. Según el Instituto Max-Planck, alrededor de 13.600 personas mueren durante cada temporada de gripe, y muchas muertes pertenecen a la población de mayor edad. En octubre de 2020, para reducir el riesgo de brotes simultáneos de influenza y COVID-19, Alemania ordenó 6 millones de dosis adicionales de vacuna contra la influenza. Además, según el Instituto Robert Koch, en 2019 se observó un aumento en los casos de hepatitis E y leptospirosis debido a una mayor conciencia sobre estas enfermedades por parte de los médicos y al aumento de las pruebas de laboratorio. Alemania ha estado a la vanguardia del desarrollo de nuevas tecnologías y terapias debido a su infraestructura bien desarrollada y su alta inversión. La presencia de eminentes institutos de investigación ha llevado al lanzamiento de terapias innovadoras. El aumento de los lanzamientos de productos es el factor principal que impulsa el crecimiento del mercado virológico europeo.
Las epidemias de virus emergentes ocurren inesperadamente y demandan rápidamente acciones para detener la propagación de la enfermedad. El brote más reciente de COVID-19 en todo el mundo pone de relieve la necesidad de desarrollar diagnósticos, vacunas y medicamentos antivirales con urgencia. Como el COVID-19 pertenece a la familia de los coronavirus, gran parte de la investigación sobre el MERS y el desarrollo de vacunas contra él permitieron el rápido avance de las vacunas contra el COVID-19. Por lo tanto, desarrollar prototipos de vacunas contra virus potenciales podría acelerar en gran medida el desarrollo de vacunas contra cualquier pandemia emergente. Por ejemplo, antes de la COVID-19, la Coalición para Innovaciones en Preparación para Epidemias (CEPI) había desarrollado una sólida cartera de candidatas a vacunas contra el MERS e invirtió más de 140 millones de dólares en el desarrollo de la vacuna, que más tarde sentó las bases para una respuesta rápida a la COVID-19. y permitió el rápido desarrollo de la vacuna COVID-19, incluida la vacuna Oxford. Además, CEPI estableció una colaboración con la Universidad de Oxford en 2018 para desarrollar una vacuna contra el MERS utilizando su plataforma de vacunas ChadOx. CEPI proporcionó financiación adicional a la Universidad de Oxford para adaptar esta plataforma tecnológica al desarrollo de una vacuna contra el COVID-19. Para ampliar la fabricación de su vacuna candidata contra la COVID-19, la Universidad de Oxford se asoció posteriormente con AstraZeneca, quien se comprometió a producir la vacuna sin fines de lucro durante la pandemia. Por lo tanto, la preparación para una pandemia ha ayudado a lanzar vacunas en un período corto, lo que enfatiza aún más la necesidad de una mayor inversión en la investigación de virus emergentes. Europa lleva mucho tiempo invirtiendo en la investigación de virus emergentes. El Centro ha aportado experiencia a los recientes brotes de ébola y ahora está trabajando en COVID-19. Además, las aprobaciones de vacunas han aumentado las esperanzas de superar eventualmente la pandemia. Sin embargo, los brotes recientes y la aparición de nuevas cepas del virus afectan los resultados económicos, y una pospandemia requerirá que los gobiernos y el sector privado asuman compromisos duraderos con la preparación global para epidemias y pandemias.
Visión general y dinámica del mercado
Se espera que el mercado de virología en Europa crezca de 1.208,26 millones de dólares en 2021 a 1.521,97 millones de dólares en 2028; se estima que crecerá a una tasa compuesta anual del 3,4% de 2021 a 2028. Las vacunas y los productos biofarmacéuticos de origen vegetal no necesitan costosos sistemas de fermentación y purificación ni otros costos asociados con el almacenamiento en frío, el transporte y la distribución estéril cuando se administran por vía oral. En general, los cloroplastos ofrecen altos niveles de expresión de antígenos vacunales contra patógenos y productos biofarmacéuticos bacterianos, virales y protozoarios y la contención de transgenes por herencia materna. En los últimos ocho años, se ha establecido el sistema de cloroplastos para la expresión de proteínas terapéuticas. Además, el reciente desarrollo de un sistema eficiente de cloroplastos de lechuga para administración oral es un avance significativo. Además, el diagnóstico de salud en el hogar está ganando popularidad entre los pacientes. Como respuesta al mercado de la virología, los actores están desarrollando kits de prueba caseros que ayudan a realizar un diagnóstico fácil y rápido y a tomar un tratamiento médico inmediato.
Segmentos clave del mercado
El mercado europeo de virología está segmentado según el tipo, la aplicación, el usuario final y el país. Según el tipo, el mercado se segmenta en pruebas de diagnóstico, técnicas de control de infecciones virales, terapias antivirales e interferones. El segmento de terapias antivirales dominó el mercado en 2020, y se espera que el segmento de técnicas de control de infecciones virales sea el de más rápido crecimiento durante el período de pronóstico. El segmento de pruebas de diagnóstico se clasifica además en pruebas de virus de ADN, pruebas de virus de ARN y otras. De manera similar, las técnicas de control de infecciones virales se dividen en profilaxis activa y profilaxis pasiva. Asimismo, la terapéutica antiviral segmentada se clasifica en agentes virucidas, agentes antivirales, inmunomoduladores e interferones. Según la aplicación, el mercado de la virología se segmenta en infecciones de la piel y tejidos blandos, infecciones del tracto respiratorio, infecciones del tracto gastrointestinal, enfermedades de transmisión sexual, infecciones del tracto urinario y otras. El segmento de infecciones del tracto respiratorio dominó el mercado en 2020 y se espera que sea el de más rápido crecimiento durante el período previsto. Según el usuario final, el mercado de la virología se segmenta en hospitales, laboratorios de diagnóstico, empresas farmacéuticas y biotecnológicas e institutos académicos y de investigación. El segmento de hospitales dominó el mercado en 2020 y se espera que el segmento de laboratorios de diagnóstico sea el de más rápido crecimiento durante el período de pronóstico.
Principales fuentes y empresas cotizadas
Algunas de las principales fuentes primarias y secundarias a las que se hace referencia para preparar este informe sobre el mercado de la virología en Europa son los sitios web de las empresas, los informes anuales, los informes financieros, los documentos de los gobiernos nacionales y las bases de datos estadísticas, entre otros. Las principales empresas que figuran en el informe son Abbott; AbbVie Inc.; F. Hoffmann-La Roche Ltd.; Ciencias de Gilead, Inc.; GlaxoSmithKline Plc; Illumina, Inc.; Johnson y Johnson Services, Inc.; QIAGEN; Siemens AG; y Thermo Fisher Scientific Inc. son, entre otros.
Informe de razones para comprar
- Comprender el panorama del mercado europeo de virología e identificar los segmentos de mercado que tienen más probabilidades de garantizar un fuerte retorno
- Manténgase a la vanguardia comprendiendo el panorama competitivo en constante cambio para el mercado de virología de Europa
- Planifique de manera eficiente fusiones y adquisiciones y acuerdos de asociación en el mercado de virología de Europa identificando segmentos de mercado con las ventas probables más prometedoras
- Ayuda a tome decisiones comerciales informadas a partir de un análisis perspicaz y completo del desempeño del mercado de varios segmentos del mercado de virología de Europa
- Obtenga pronósticos de ingresos de mercado para varios segmentos de 2021 a 2028 en la región de Europa.
Segmentación del mercado europeo de virología
Mercado europeo de virología: por tipo
- Pruebas de Diagnóstico
- Pruebas de Virus ADN
- Pruebas de Virus ARN
- Otros
- Técnicas de control de infecciones virales
- Profilaxis activa
- Profilaxis pasiva
- Terapéuticas antivirales
- Agentes virucidas
- Agentes antivirales
- Inmunomoduladores
- Interferones
Europa Mercado de virología: por Aplicación
- Infecciones de la piel y tejidos blandos
- Respiratorias Infecciones del tracto
- Infecciones del tracto gastrointestinal
- Enfermedades de transmisión sexual
- Infecciones del tracto urinario
- Otras
Mercado europeo de virología: por usuario final
- Hospitales
- Laboratorios de diagnóstico
- Farmacéuticos y empresas biotecnológicas
- Institutos académicos y de investigación
Mercado europeo de virología: por país
< ul>Mercado europeo de virología:Perfiles de empresas
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Virology Market – By Type
1.3.2 Europe Virology Market – By Application
1.3.3 Europe Virology Market – By End User
1.3.4 Europe Virology Market– By Country
2. Europe Virology Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Virology Market– Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Virology Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Viral Infectious Diseases
5.1.2 Increasing Product Launches
5.2 Market Restraints
5.2.1 Availability of Alternative Products and High Cost of Production of Products
5.3 Market Opportunities
5.3.1 Growth Potential in Several Economies
5.4 Future Trends
5.4.1 Continuous Demand for Cost-Effective Products
5.5 Impact Analysis
6. Virology Market– Europe Analysis
6.1 Europe Virology Market Revenue Forecast and Analysis
7. Europe Virology Market Analysis – By Type
7.1 Overview
7.2 Europe Virology Market Revenue Share, by Type (2021 and 2028)
7.3 Diagnostic Test
7.3.1 Overview
7.3.2 Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Deoxyribonucleic Acid (DNA) Virus Testing
7.3.2.1.1 Overview
7.3.2.1.2 DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Ribonucleic Acid (RNA) Virus Testing
7.3.2.2.1 Overview
7.3.2.2.2 RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Others
7.3.2.3.1 Overview
7.3.2.3.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Viral Infection Controlling Techniques
7.4.1 Overview
7.4.2 Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Active Prophylaxis
7.4.2.1.1 Overview
7.4.2.1.2 Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Passive Prophylaxis
7.4.2.2.1 Overview
7.4.2.2.2 Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Antiviral Therapeutics
7.5.1 Overview
7.5.2 Antiviral Therapeutics: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Virucidal Agents
7.5.2.1.1 Overview
7.5.2.1.2 Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Antiviral Agents
7.5.2.2.1 Overview
7.5.2.2.2 Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Immunomodulators
7.5.2.3.1 Overview
7.5.2.3.2 Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Interferons
7.6.1 Overview
7.6.2 Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8. Europe Virology Market Analysis – By Application
8.1 Overview
8.2 Europe Virology Market, by Application 2021 & 2028 (%)
8.3 Skin and Soft Tissue Infections
8.3.1 Overview
8.3.2 Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Respiratory Tract Infections
8.4.1 Overview
8.4.2 Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.5 GI Tract Infections
8.5.1 Overview
8.5.2 GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Sexually Transmitted Diseases
8.6.1 Overview
8.6.2 Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Urinary Tract Infections
8.7.1 Overview
8.7.2 Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Virology Market Analysis – By End User
9.1 Overview
9.2 Europe Virology Market Revenue Share, by End User (2021 and 2028)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Pharmaceutical and Biotechnological Companies
9.5.1 Overview
9.5.2 Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Research and Academic Institutes
9.6.1 Overview
9.6.2 Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
10. Europe Virology Market – Country Analysis
10.1.1 Europe Virology Market Revenue and Forecasts to 2028, By Country (%)
10.1.1.1 UK Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.1.1 UK Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.1.2 UK Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.1.2.1 UK: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.1.2.2 UK: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.1.2.3 UK: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.1.3 UK Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.1.4 UK Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.2 Germany Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.2.1 Germany Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.2.2 Germany Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.2.2.1 Germany: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.2.2.2 Germany: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.2.2.3 Germany: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.2.3 Germany Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.2.4 Germany Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.3 France Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.3.1 France Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.3.2 France Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.3.2.1 France: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.3.2.2 France: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.3.2.3 France: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.3.3 France Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.3.4 France Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.4 Italy Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.4.1 Italy Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.4.2 Italy Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.4.2.1 Italy: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.4.2.2 Italy: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.4.2.3 Italy: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.4.3 Italy Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.4.4 Italy Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.5 Spain Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.5.1 Spain Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.5.2 Spain Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.5.2.1 Spain: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.5.2.2 Spain: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.5.2.3 Spain: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.5.3 Spain Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.5.4 Spain Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
10.1.1.6 Rest of Europe Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.6.1 Rest of Europe Virology Market Revenue and Forecasts to 2028 (US$ million)
10.1.1.6.2 Rest of Europe Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
10.1.1.6.2.1 Rest of Europe: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.1.6.2.2 Rest of Europe: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.1.6.2.3 Rest of Europe: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.1.6.3 Rest of Europe Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
10.1.1.6.4 Rest of Europe Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
11. Impact of COVID-19 Pandemic on Europe Virology Market
11.1 Overview
12. Europe Virology Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Abbott
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Johnson and Johnson Services, Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 F. HOFFMANN-LA ROCHE LTD.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 QIAGEN
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Illumina, Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 GlaxoSmithKline Plc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 AbbVie Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Gilead Sciences, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Virology Market Revenue and Forecast to 2028 (US$ Million)
Table 2. UK Virology Market Revenue and Forecasts to 2028, By Type US$ million)
Table 3. UK Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 4. UK Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 5. UK Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 6. UK Virology Market Revenue and Forecasts to 2028, by Application US$ million)
Table 7. UK Virology Market Revenue and Forecasts to 2028, by End User US$ million)
Table 8. Germany Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 9. Germany Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 10. Germany Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 11. Germany Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 12. Germany Virology Market Revenue and Forecasts to 2028, by Application US$ million)
Table 13. Germany Virology Market Revenue and Forecasts to 2028, by End User US$ million)
Table 14. France Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 15. France Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 16. France Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 17. France Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 18. France Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
Table 19. France Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
Table 20. Italy Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 21. Italy Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 22. Italy Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 23. Italy Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 24. Italy Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
Table 25. Italy Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
Table 26. Spain Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 27. Spain Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 28. North America Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 29. Spain Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 30. Spain Virology Market, by Application – Revenue and Forecast to 2028 by Application (USD Million)
Table 31. Spain Virology Market, by End User – Revenue and Forecast to 2028 by End User (USD Million)
Table 32. Rest of Europe Virology Market Revenue and Forecasts to 2028, By Type (US$ million)
Table 33. Rest of Europe Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 34. Rest of Europe Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 35. Rest of Europe Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 36. Rest of Europe Virology Market Revenue and Forecasts to 2028, by Application (US$ million)
Table 37. Rest of Europe Virology Market Revenue and Forecasts to 2028, by End User (US$ million)
Table 38. Organic Developments Done by Companies
Table 39. Inorganic Developments Done by Companies
Table 40. Glossary of Terms, Europe Virology Market
LIST OF FIGURES
Figure 1. Europe Virology Market Segmentation
Figure 2. Europe Virology Segmentation, By Country
Figure 3. Europe Virology Market Overview
Figure 4. Antiviral Therapeutics Held the Largest Share of the Type Segment in Europe Virology Market
Figure 5. Respiratory Tract Infections Held the Largest Share of the Application Segment in Europe Virology Market
Figure 6. UK to Show Significant Growth During Forecast Period
Figure 7. Europe and PEST Analysis
Figure 8. Europe Virology Market: Impact Analysis of Drivers and Restraints
Figure 9. Europe Virology Market– Revenue Forecast and Analysis – 2019- 2028
Figure 10. Europe Virology Market Revenue Share, by Type (2021 and 2028)
Figure 11. Europe Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Europe DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Europe RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Europe Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Europe Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Europe Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Europe Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Europe Antiviral Therapeutics : Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Europe Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Europe Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Europe Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Europe Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Europe Virology Market, by Application 2021 & 2028 (%)
Figure 24. Europe Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Europe Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Europe GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Europe Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Europe Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Europe Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Europe Virology Market Revenue Share, by End User (2021 and 2028)
Figure 31. Europe Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Europe Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Europe Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Europe Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Europe: Virology Market Revenue Overview, by Country, 2021 (US$ MN)
Figure 36. Europe Virology Market Revenue and Forecasts to 2028, By Country (%)
Figure 37. UK Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 38. Germany Virology Products Market Revenue and Forecasts to 2028 (US$ million)
Figure 39. France Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 40. Italy Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 41. Spain Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 42. Rest of Europe Virology Market Revenue and Forecasts to 2028 (US$ million)
Figure 43. Impact of COVID-19 Pandemic on Virology Market in European Countries
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe Virology market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe Virology market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Virology market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution